Genetics of Pancreatic Cancer and Its Implications on Therapy.
Publication/Presentation Date
12-1-2016
Abstract
Over the past decade, emerging technologies have provided new insights into the genomic landscape of pancreatic ductal adenocarcinoma (PDA). In addition to the commonly recognized genetic drivers of pancreatic carcinogenesis (KRAS, CDKN2A, TP53, SMAD4), new genes and pathways have been implicated. However, these efforts have not identified any new high-frequency actionable mutations, limiting the success of mutation-targeted therapy in PDA. This article provides a report on the current landscape of pancreas cancer genetics and targeted therapeutics.
Volume
96
Issue
6
First Page
1207
Last Page
1221
ISSN
1558-3171
Published In/Presented At
Tatarian, T., & Winter, J. M. (2016). Genetics of Pancreatic Cancer and Its Implications on Therapy. The Surgical clinics of North America, 96(6), 1207–1221. https://doi.org/10.1016/j.suc.2016.07.014
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
27865273
Department(s)
Administration and Leadership
Document Type
Article